Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Rating Upgraded by Wall Street Zen

Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Sunday.

Several other equities research analysts have also recently weighed in on the company. Maxim Group cut Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, April 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research report on Tuesday, April 21st. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $66.67.

Reviva Pharmaceuticals Price Performance

Shares of NASDAQ:RVPH opened at $0.66 on Friday. Reviva Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $17.20. The stock has a market capitalization of $8.65 million, a P/E ratio of -0.16 and a beta of 0.47. The firm has a fifty day simple moving average of $0.64 and a two-hundred day simple moving average of $3.18.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.10). On average, analysts expect that Reviva Pharmaceuticals will post -2.96 earnings per share for the current year.

Institutional Trading of Reviva Pharmaceuticals

A number of large investors have recently made changes to their positions in the stock. Armistice Capital LLC bought a new position in shares of Reviva Pharmaceuticals in the second quarter worth about $1,026,000. Geode Capital Management LLC lifted its holdings in Reviva Pharmaceuticals by 87.6% during the 4th quarter. Geode Capital Management LLC now owns 1,048,954 shares of the company’s stock valued at $293,000 after buying an additional 489,711 shares in the last quarter. State Street Corp boosted its position in Reviva Pharmaceuticals by 202.4% in the 4th quarter. State Street Corp now owns 383,200 shares of the company’s stock valued at $107,000 after buying an additional 256,500 shares during the period. Millennium Management LLC boosted its position in Reviva Pharmaceuticals by 15.0% in the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock valued at $631,000 after buying an additional 223,178 shares during the period. Finally, Lido Advisors LLC bought a new position in Reviva Pharmaceuticals in the 3rd quarter worth about $37,000. 63.18% of the stock is owned by hedge funds and other institutional investors.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.